FDA Invites Feedback on Advisory Committee Info Forms
Published Date: 3/23/2026
Notice
Summary
The FDA wants your thoughts on how it collects info from its advisory committees. This is about keeping paperwork clear and easy, with no big changes or costs expected. If you have ideas, send them in by May 22, 2026, to help shape how the FDA works with experts.
No Economic Impacts Identified for this Document
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20075, Medical Devices; Gastroenterology-Urology Devices; Classification of the Flushing and Storage Solution for Vascular Autografts at Room Temperature
The FDA is officially putting the flushing and storage solution for vascular autografts at room temperature into class II, meaning it now has special safety rules but fewer regulatory hurdles. This change helps companies bring these devices to patients faster and safer, starting from September 30, 2026, with the classification effective since October 4, 2023. Medical device makers and patients will benefit from easier access to these important solutions without extra costs or delays.
2026-19968, Determination That ISTURISA (Osilodrostat) Tablets, 10 Milligrams, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
The FDA has decided that ISTURISA (osilodrostat) 10 mg tablets were not taken off the market because of safety or effectiveness problems. This means generic drug makers can now apply to sell their own versions of ISTURISA, as long as they meet all the rules. Patients and pharmacies could see more affordable options soon, with no safety worries involved.
Previous / Next Documents
Previous: 2026-05622, Application for Renewal of Authorization To Export Electric Energy; Rainbow Energy Marketing Corporation
Rainbow Energy Marketing Corporation wants to renew its permission to send extra electric energy from the U.S. to Mexico for another five years. This affects energy markets and keeps cross-border power flowing smoothly without building new power plants. If you want to speak up, you’ve got until April 22, 2026, to send your comments or protests.
Next: 2026-05624, Rio Grande LNG, LLC, Rio Grande LNG Train 4, LLC, & Rio Grande LNG Train 5, LLC; Request for Extension of Non-FTA Authorization Export Commencement Deadline
Rio Grande LNG and its related companies are asking the Department of Energy for more time to start exporting liquefied natural gas to countries without free trade deals. Their big Texas terminal is still being built, so they want to push back the deadline to get everything ready. This extension helps keep their project on track without rushing, but the public has until April 22, 2026, to share their thoughts.